Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

NAP (davunetide) provides functional and structural neuroprotection.

Gozes I.

Curr Pharm Des. 2011;17(10):1040-4. Review.

PMID:
21524250
2.

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

Gozes I.

Curr Pharm Des. 2011;17(31):3413-7. Review.

PMID:
21902667
3.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
4.

Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.

Gozes I.

Peptides. 2011 Feb;32(2):428-31. doi: 10.1016/j.peptides.2010.10.030. Epub 2010 Nov 2. Review.

PMID:
21050875
5.

Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy.

Sokolowska P, Passemard S, Mok A, Schwendimann L, Gozes I, Gressens P.

Neuroscience. 2011 Jan 26;173:156-68. doi: 10.1016/j.neuroscience.2010.10.074. Epub 2010 Nov 10.

PMID:
21073926
6.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
7.

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.

Zemlyak I, Manley N, Vulih-Shultzman I, Cutler AB, Graber K, Sapolsky RM, Gozes I.

J Neurochem. 2009 Dec;111(5):1252-63. doi: 10.1111/j.1471-4159.2009.06415.x. Epub 2009 Oct 3.

8.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

9.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
10.

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

Magen I, Gozes I.

Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.

PMID:
24210139
11.
12.

The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.

Gozes I.

Biol Chem. 2016 Mar;397(3):177-84. doi: 10.1515/hsz-2015-0152. Review.

PMID:
25955282
13.

ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.

Gozes I, Ivashko-Pachima Y.

Front Aging Neurosci. 2015 Oct 29;7:205. doi: 10.3389/fnagi.2015.00205. eCollection 2015. Review.

14.

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I.

Neurobiol Dis. 2009 May;34(2):381-8. doi: 10.1016/j.nbd.2009.02.011. Epub 2009 Mar 2.

PMID:
19264130
15.
17.

NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.

Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I.

Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22.

PMID:
20417241
18.

Activity-dependent neuroprotective protein: from gene to drug candidate.

Gozes I.

Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.

PMID:
17363064
19.

NAP alpha-aminoisobutyric acid (IsoNAP).

Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.

J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.

PMID:
24458740
20.

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L.

CNS Drug Rev. 2005 Winter;11(4):353-68. Review.

Supplemental Content

Support Center